Already, these dual-targeting mechanisms of H9 combined with trastuzumab exerted stronger anti-cancer activity by inhibiting PI3K/AKT and activating AMPK than did either drug individually, producing a synergistic effect by inducing apoptosis in mice bearing a breast tumor with combination index (CI) values less than 1 (CI = 0.647) [20,32,37,38]. The gene discussed is AKT1; the disease is cancer.